Abstract
The first formal qualification of safety biomarkers for regulatory decision making marks a milestone in the application of biomarkers to drug development. Following submission of drug toxicity studies and analyses of biomarker performance to the Food and Drug Administration (FDA) and European Medicines Agency (EMEA) by the Predictive Safety Testing Consortium's (PSTC) Nephrotoxicity Working Group, seven renal safety biomarkers have been qualified for limited use in nonclinical and clinical drug development to help guide safety assessments. This was a pilot process, and the experience gained will both facilitate better understanding of how the qualification process will probably evolve and clarify the minimal requirements necessary to evaluate the performance of biomarkers of organ injury within specific contexts.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Goodsaid, F. & Papaluca, M. Evolution of biomarker qualification at the health authorities. Nat. Biotechnol. 28, 441–443 (2010).
Altar, C.A. et al. A prototypical process for creating evidentiary standards for biomarkers and diagnostics. Clin. Pharmacol. Ther. 83, 368–371 (2008).
Ozer, J.S. A panel of urinary biomarkers to monitor reversibility of renal injury and a serum marker with improved potential to assess renal function. Nat. Biotechnol. 28, 486–494 (2010).
Varghese, S.A. et al. Urine biomarkers predict the cause of glomerular disease. J. Am. Soc. Nephrol. 18, 913–922 (2007).
Comper, W.D., Hilliard, L.M., Nikolic-Paterson, D.J. & Russo, L.M. Disease-dependent mechanisms of albuminuria. Am. J. Physiol. Renal Physiol. 295, F1589–F1600 (2008).
Trof, R.J., Di Maggio, F., Leemreis, J. & Groeneveld, A.B. Biomarkers of acute renal injury and renal failure. Shock 26, 245–253 (2006).
Dieterle, F. et al. Urinary clusterin, cystatin C, β2-microglobulin and total protein as markers to detect drug-induced kidney injury. Nat. Biotechnol. 28, 463–469 (2010).
DeLong, E.R., DeLong, D.M. & Clarke-Pearson, D.L. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 44, 837–845 (1988).
Harrell, F. Regression Modeling Strategies (Springer, New York, 2001).
Lee, J.W. et al. Fit-for-purpose method development and validation for successful biomarker measurement. Pharm. Res. 23, 312–328 (2006).
Sistare, F. et al. Towards consensus practices to qualify safety biomarkers for use in early drug development. Nat. Biotechnol. 28, 446–454 (2010).
Bonventre, J.V., Vaidya, V.S., Schmouder, R., Feig, P. & Dieterle, F. Next-generation biomarkers for detecting kidney toxicity. Nat. Biotechnol. 28, 436–440 (2010).
Author information
Authors and Affiliations
Contributions
Members of the PSTC Nephrotoxicity Working Group compiling the submission for biomarker qualification: F.D., F.S., J.S.O., C.P.W., W.B., A.S., M.J.S., J.V., S.S., D.L.G., J.A.P., G.M., K.C., D.L., E.H., M.S., D.E., D.H., D.A.-C., Y.-Z.G., K.L.T., P.L.G., J.-M.V., S.T., D.B., D.R.-G., G.B., M.A.D., J.A., J.E.MD., L.S.-D., L.O., M.G., M. Papaluca, S.J., E.A.B., S.A.B., V.G.B., N.C., J.W., D.H., S.S., J.L., P.R., E.W. and W.M.; members of the FDA Biomarker Qualification Review Team, reviewing the submission for biomarker qualification: F.G., D.J.-K., A.F.D., E.A.H., M.B., A.T., P.H., D.T., S.X., W.T. and N.X.; members of the EMEA Biomarker Qualification Review Team, reviewing the submission for biomarker qualification: M. Papaluca, J.-M.V., E.A., R.M., S.V., B.F., B.S.L., P.K., M. Pasanen and K.P.
Corresponding author
Ethics declarations
Competing interests
F.D., G.M., K.C. and D.L. are employees of Novartis; F.S., D.H., S.T., Y.-Z.G., N.C. and D.L.G. are employees of Merck; W.B., A.S., M.J.S. and S.S. are employees of ClinXus; C.P.W. is an employee of Van Andel Research Institute; W.B. is an employee of Grand Valley Medical Specialists; A.S. is an employee of Spectrum Health; M.J.S. is an employee of Innovative Analytics; J.V. and L.S. are employees of Hoffman-La Roche; J.A.P. and S.J. are employees of Boehringer Ingelheim; E.H., M.G. and V.G.B. are employees of Sanofi-Aventis; M.S., J.E.M. and S.S. are employees of Johnson & Johnson; D.E. is an employee of GlaxoSmithKline; D.A.-C. is an employee of Amgen; D.B. is an employee of Bristol-Myers Squibb; D.R.-G., L.O. and S.A.B. are employees of Pfizer; G.B. and M.P. are employees of AstraZeneca; J.A. is an employee of Eli Lilly; E.A.B., J.W., D.H. and J.L. are employees of Abbott; J.S.O. was an employee of Merck.
Rights and permissions
About this article
Cite this article
Dieterle, F., Sistare, F., Goodsaid, F. et al. Renal biomarker qualification submission: a dialog between the FDA-EMEA and Predictive Safety Testing Consortium. Nat Biotechnol 28, 455–462 (2010). https://doi.org/10.1038/nbt.1625
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt.1625
This article is cited by
-
Detection, Monitoring, and Mitigation of Drug-Induced Nephrotoxicity: A Pragmatic Approach
Therapeutic Innovation & Regulatory Science (2024)
-
A magnetic solid phase chemiluminescent immunoassay for quantification of Cystatin C in human serum
BMC Biotechnology (2023)
-
Circulating microRNAs as promising testicular translatable safety biomarkers: current state and future perspectives
Archives of Toxicology (2023)
-
Drug toxicity in the proximal tubule: new models, methods and mechanisms
Pediatric Nephrology (2022)
-
Serial serum creatinine, SDMA and urinary acute kidney injury biomarker measurements in dogs envenomated by the European adder (Vipera berus)
BMC Veterinary Research (2021)